+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

IDWeek 2026: Pre-Conference Coverage

  • PDF Icon

    Report

  • 14 Pages
  • October 2026
  • Region: Global
  • GlobalData
  • ID: 6189740

IDWeek 2026: Pre-Conference Coverage

Summary

The IDWeek Global Annual Meeting 2026 will take place in Washington, DC, US from October 21-24.

Use this report to:

Prepare for IDWeek 2026 by reviewing high-impact, potentially practice-changing abstracts, including those of breakthrough therapies that could redefine treatment paradigms.

This report also spotlights emerging therapies that may not yet be widely recognized but represent significant clinical and commercial opportunities.

Scope

Indications, companies, and therapies discussed:

  • Invasive aspergillosis (IA)
  • Olorofim - F2G and Shionogi
  • HIV-related cryptococcal meningitis
  • Turletricin - Elion Therapeutics
  • Respiratory syncytial virus (RSV)
  • Abrysvo - Pfizer
  • COVID-19
  • Xocova/Zokovea (ensitrelvir) - Shionogi
  • HIV
  • Islatravir/Lenacapavir (ISL/LEN) - Gilead and Merck
  • Genital herpes
  • BNT163 - BioNTech
  • Pneumococcal disease
  • PCV25 - Pfizer
  • Lyme disease
  • LB6V - Valneva and Pfizer
  • Hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP)
  • Meropenem-pilabactam (MEM-PIL) - Antabio

Reasons to Buy

  • This powerpoint-based deliverable highlights noteworthy conference abstracts, and the potential implications for your strategy, covering disease areas such as Lyme disease, aspergillosis, RSV, COVID-19, HIV, genital herpes, and more.

Table of Contents

1. Introduction

2. Key Presentations
2.1. Invasive Aspergillosis - Olorofim
2.2. HIV-related cryptococcal meningitis - Turletricin
2.3. Respiratory syncytial virus (RSV) - Abrysvo
2.4. COVID-19 - Xocova/Zokovea (ensitrelvir)
2.5. HIV - Islatravir/Lenacapavir (ISL/LEN)
2.6. Genital herpes - BNT163
2.7. Pneumococcal disease - PCV25
2.8. Lyme disease - LB6V
2.9. Hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) - Meropenem-pilabactam (MEM-PIL)

3. Appendix
3.1. About the Authors
3.2. About the Analyst
3.3. Contact Us

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • F2G
  • Elion Therapeutics
  • Pfizer
  • Shionogi
  • Gilead
  • Merck
  • BioNTech
  • Valneva
  • Antabio